SCHEMBL1637587

SCHEMBL1637587

Cc1nnsc1C(=O)N/N=C\c1cc(Cl)ccc1O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.60
KMT2A Q03164 8/20 0.60
KDM4E B2RXH2 6/20 0.60
HTT P42858 5/20 0.60
LMNA P02545 5/20 0.60
L3MBTL1 Q9Y468 2/20 0.60
MAPT P10636 2/20 0.60
TP53 P04637 2/20 0.60
PIK3CG P48736 1/20 0.60
RAB9A P51151 4/20 0.59
NPC1 O15118 3/20 0.59
MITF O75030 3/20 0.59
GPR174 Q9BXC1 1/20 0.59
KDM1A O60341 2/20 0.58
POLB P06746 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
PSMD14 O00487 1/20 0.56
MMP2 P08253 1/20 0.56
BLM P54132 1/20 0.56
KLF5 Q13887 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12766844 1.00 MEN1 (0.60) MEN1KMT2AKDM4EHTTLMNA
SCHEMBL1637589 1.00 MEN1 (0.60) MEN1KMT2AKDM4EHTTLMNA
SCHEMBL1639292 0.79 PIK3CG (0.60) MEN1KMT2AKDM4EHTTLMNA
SCHEMBL1639291 0.79 PIK3CG (0.60) MEN1KMT2AKDM4EHTTLMNA
SCHEMBL12766641 0.79 PIK3CG (0.60) MEN1KMT2AKDM4EHTTLMNA
SCHEMBL684527 0.77 KDM1A (0.81) MEN1KMT2AKDM4EHTTLMNA
SCHEMBL684605 0.77 KDM1A (0.72) MEN1KMT2AKDM4EHTTLMNA
SCHEMBL6568342 0.76 KDM1A (0.89) MEN1KMT2AKDM4EHTTLMNA
SCHEMBL6568344 0.76 KDM1A (0.89) MEN1KMT2AKDM4EHTTLMNA
SCHEMBL683818 0.76 KDM1A (0.89) MEN1KMT2AKDM4EHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US claimed
EP-2194975-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS Acumen Pharmaceuticals, Inc. (US) 2010-06-16 EP claimed
WO-2009009768-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS ACUMEN PHARMACEUTICALS, INC. (US) 2009-01-15 WO claimed
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
EP-2194975-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS Acumen Pharmaceuticals, Inc. (US) 2010-06-16 EP disclosed
WO-2009009768-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS ACUMEN PHARMACEUTICALS, INC. (US) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS APP, APBA1, BACE1 MEN1 2974/4885KMT2A 3625/4885KDM4E 4638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.